These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12142643)

  • 1. Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients.
    Mihara K; Yasui-Furukori N; Kondo T; Ishida M; Ono S; Ohkubo T; Osanai T; Sugawara K; Otani K; Kaneko S
    Ther Drug Monit; 2002 Aug; 24(4):563-6. PubMed ID: 12142643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increases in plasma concentration of m-chlorophenylpiperazine, but not trazodone, with low-dose haloperidol.
    Mihara K; Otani K; Ishida M; Yasui N; Suzuki A; Ohkubo T; Osanai T; Kaneko S; Sugawara K
    Ther Drug Monit; 1997 Feb; 19(1):43-5. PubMed ID: 9029745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of genetic polymorphism of CYP1A2 inducibility on the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine in depressed Japanese patients.
    Mihara K; Kondo T; Suzuki A; Yasui-Furukori N; Ono S; Otani K; Kaneko S
    Pharmacol Toxicol; 2001 May; 88(5):267-70. PubMed ID: 11393588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine.
    Mihara K; Otani K; Suzuki A; Yasui N; Nakano H; Meng X; Ohkubo T; Nagasaki T; Kaneko S; Tsuchida S; Sugawara K; Gonzalez FJ
    Psychopharmacology (Berl); 1997 Sep; 133(1):95-8. PubMed ID: 9335086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine.
    Otani K; Ishida M; Kaneko S; Mihara K; Ohkubo T; Osanai T; Sugawara K
    Ther Drug Monit; 1996 Apr; 18(2):164-7. PubMed ID: 8721280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma concentrations of trazodone and m-chlorophenylpiperazine at steady state can be predicted from those after an initial dose of trazodone.
    Otani K; Mihara K; Yasui N; Ishida M; Kondo T; Tokinaga N; Ohkubo T; Osanai T; Sugawara K; Kaneko S
    Prog Neuropsychopharmacol Biol Psychiatry; 1997 Jan; 21(1):239-44. PubMed ID: 9075270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine.
    Ishida M; Otani K; Kaneko S; Ohkubo T; Osanai T; Yasui N; Mihara K; Higuchi H; Sugawara K
    Int Clin Psychopharmacol; 1995 Sep; 10(3):143-6. PubMed ID: 8675966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of trazodone metabolism by thioridazine in humans.
    Yasui N; Otani K; Kaneko S; Ohkubo T; Osanai T; Ishida M; Mihara K; Kondo T; Sugawara K; Fukushima Y
    Ther Drug Monit; 1995 Aug; 17(4):333-5. PubMed ID: 7482685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trazodone treatment increases plasma prolactin concentrations in depressed patients.
    Otani K; Yasui N; Kaneko S; Ishida M; Ohkubo T; Osanai T; Sugawara K; Fukushima Y
    Int Clin Psychopharmacol; 1995 Jun; 10(2):115-7. PubMed ID: 7673654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between steady-state plasma concentrations of mianserin and trazodone in depressed patients.
    Otani K; Tybring G; Mihara K; Yasui N; Kaneko S; Ohkubo T; Nagasaki T; Sugawara K
    Eur J Clin Pharmacol; 1998 Jan; 53(5):347-9. PubMed ID: 9516035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.
    Gerstenberg G; Aoshima T; Fukasawa T; Yoshida K; Takahashi H; Higuchi H; Murata Y; Shimoyama R; Ohkubo T; Shimizu T; Otani K
    Psychopharmacology (Berl); 2003 Jun; 167(4):443-8. PubMed ID: 12682708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-performance liquid chromatographic determination of trazodone and 1-m-chlorophenylpiperazine with ultraviolet and electrochemical detector.
    Ohkubo T; Osanai T; Sugawara K; Ishida M; Otani K; Mihara K; Yasui N
    J Pharm Pharmacol; 1995 Apr; 47(4):340-4. PubMed ID: 7791034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for a linear relationship between plasma trazodone levels and clinical response in depression in the elderly.
    Monteleone P; Gnocchi G
    Clin Neuropharmacol; 1990; 13 Suppl 1():S84-9. PubMed ID: 2379183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPLC analysis of the antidepressant trazodone and its main metabolite m-CPP in human plasma.
    Mercolini L; Colliva C; Amore M; Fanali S; Raggi MA
    J Pharm Biomed Anal; 2008 Aug; 47(4-5):882-7. PubMed ID: 18400445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of trazodone and its metabolite, 1-m-chlorophenyl-piperazine, in human plasma and red blood cell samples by HPLC.
    Vatassery GT; Holden LA; Hazel DK; Dysken MW
    Clin Biochem; 1997 Mar; 30(2):149-53. PubMed ID: 9127697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine.
    Wen B; Ma L; Rodrigues AD; Zhu M
    Drug Metab Dispos; 2008 May; 36(5):841-50. PubMed ID: 18238857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of plasma and brain concentrations of trazodone and its metabolite, 1-m-chlorophenylpiperazine, by gas-liquid chromatography.
    Caccia S; Ballabio M; Fanelli R; Guiso G; Zanini MG
    J Chromatogr; 1981 Jun; 210(2):311-8. PubMed ID: 7263792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients.
    Mihara K; Otani K; Tybring G; Dahl ML; Bertilsson L; Kaneko S
    J Clin Psychopharmacol; 1997 Dec; 17(6):467-71. PubMed ID: 9408809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder.
    Sheehan DV; Rozova A; Gossen ER; Gibertini M
    Psychopharmacol Bull; 2009; 42(4):5-22. PubMed ID: 20581790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time course of clinical response to venlafaxine: relevance of plasma level and chirality.
    Gex-Fabry M; Balant-Gorgia AE; Balant LP; Rudaz S; Veuthey JL; Bertschy G
    Eur J Clin Pharmacol; 2004 Feb; 59(12):883-91. PubMed ID: 14704834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.